Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
RESEARCH TOOLSreports
Holding GB:0HJ7?
Track your performance easily
0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Atossa Therapeutics News
PremiumCompany Announcements
Atossa Therapeutics: Q3 2024 Financial Results and Updates
Options Prices
Currently, No data available
---
Ownership Overview
7.29% Insiders
8.02% Mutual Funds
0.29% Other Institutional Investors
75.14% Public Companies and
Individual Investors
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 125,801,254 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
---
Atossa Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (― Upside)
$5.50 (― Upside)
Blogger Sentiment
Bullish
GB:0HJ7 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.28%
12-Months-Change
Fundamentals
Return on Equity
-31.30%
Trailing 12-Months
Asset Growth
-21.85%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
---
0HJ7 Earnings Call
Q2 2023
0:00 / 0:00
---
0HJ7 Stock 12 Month Forecast
Average Price Target
―Best Analysts Covering 0HJ7
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+11.17%
assigned a buy rating 11 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.17% per trade.
---